FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#1 | |||
|
||||
Senior Member
|
[Really--amgen spent 19% on R and D last year? and that's way too much?????]
The Disconnect Continues: Amgen Rethinks R&D By Ed Silverman // October 13th, 2011 // 9:08 am Taking a page from the big pharma playbook, Amgen is planning to reorganize its R&D operations. And sources says the biotech plans to cut a chunk of the budget and may place less emphasis on discovery. Such a move would mimic what many big drugmakers have been doing in recent years as they attempt to lower their costs and seek the next big-selling molecule elsewhere. ... Amgen, by the way, employs a total of 17,000 people worldwide. ...Cutting R&D would make Wall Street happy. Amgen notched $15.1 billion in revenue during its last fiscal year and spent $2.9 billion, or about 19 percent, on R&D. The $3 billion R&D line item annually is high and investors see room to start to trim this, ... ...Ironically, the R&D changes come after the Amgen board has been widely criticized for being too generous with ceo Kevin Sharer. Earlier this year, the board appeased investors by finally offering a dividend, but also hiked his overall compensation from $15 million to $21 million... http://www.pharmalot.com/2011/10/the...n-rethinks-rd/
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here it's just not very evenly distributed. William Gibson |
|||
![]() |
![]() |
|
|
![]() |
||||
Thread | Forum | |||
Amgen | Parkinson's Disease | |||
You poor poor people | Parkinson's Disease | |||
Amgen | Parkinson's Disease | |||
Amgen | Parkinson's Disease |